[
  {
    "abstract_id": "ADA-2026-OR-101",
    "title": "Retatrutide once weekly in adults with obesity and type 2 diabetes — a Phase 3 cardiometabolic outcomes interim analysis",
    "authors": "Mock A, Mock B, Mock C",
    "abstract_text": "We report a synthetic interim analysis of retatrutide (LY3437943), a triple GLP-1/GIP/glucagon agonist, in a Phase 3 cardiometabolic obesity-T2D study. Mean placebo-adjusted body weight reduction at 52 weeks was -19.4%. GI adverse events were observed in 36.8% of participants. All numbers are synthetic mock data.",
    "phase": "Phase 3",
    "weight_loss_pct": 19.4,
    "gi_ae_pct": 36.8
  },
  {
    "abstract_id": "ADA-2026-OR-102",
    "title": "Orforglipron oral GLP-1 in obesity without diabetes — Phase 3 weight-loss endpoint (synthetic dataset)",
    "authors": "Mock D, Mock E",
    "abstract_text": "Synthetic Phase 3 readout of orforglipron, a small-molecule oral GLP-1 receptor agonist. Placebo-adjusted weight loss at 72 weeks was -14.6%. GI tolerability events: 31.2%. Mock authors and mock data only.",
    "phase": "Phase 3",
    "weight_loss_pct": 14.6,
    "gi_ae_pct": 31.2
  },
  {
    "abstract_id": "ADA-2026-OR-145",
    "title": "MariTide (maridebart cafraglutide) every-monthly dosing in obesity — Phase 2b results (mock)",
    "authors": "Mock F, Mock G, Mock H",
    "abstract_text": "MariTide (AMG 133), a long-acting GLP-1/GIP receptor antibody-peptide conjugate, achieved -16.2% mean weight loss at 52 weeks in a Phase 2b mock cohort. GI events 28.5%. All values synthetic.",
    "phase": "Phase 2b",
    "weight_loss_pct": 16.2,
    "gi_ae_pct": 28.5
  },
  {
    "abstract_id": "ADA-2026-PS-201",
    "title": "Survodutide for obesity and MASLD — Phase 2 weight loss and hepatic outcomes (synthetic)",
    "authors": "Mock I, Mock J",
    "abstract_text": "Survodutide (BI 456906), a GLP-1/glucagon dual agonist, demonstrated mock placebo-adjusted weight loss of -13.8% at 46 weeks in a Phase 2 obesity cohort, with 24.0% GI AE rate. Synthetic data only.",
    "phase": "Phase 2",
    "weight_loss_pct": 13.8,
    "gi_ae_pct": 24.0
  },
  {
    "abstract_id": "ADA-2026-PS-202",
    "title": "Tirzepatide vs semaglutide head-to-head in T2D-obesity — Phase 4 mock comparator analysis",
    "authors": "Mock K, Mock L",
    "abstract_text": "A Phase 4 comparator analysis (synthetic) of tirzepatide vs semaglutide in T2D with obesity. Tirzepatide -15.1% vs semaglutide -10.9% placebo-adjusted weight loss. GI AE 27.3% vs 22.9%. Mock data.",
    "phase": "Phase 4",
    "weight_loss_pct": 15.1,
    "gi_ae_pct": 27.3
  },
  {
    "abstract_id": "ADA-2026-PS-260",
    "title": "VK2735 dual GLP-1/GIP — Phase 2 dose-finding in obesity (synthetic dataset)",
    "authors": "Mock M, Mock N",
    "abstract_text": "VK2735, a GLP-1/GIP dual receptor agonist, showed dose-dependent placebo-adjusted weight loss up to -13.1% at 13 weeks in a Phase 2 mock study. GI AE 22.7%. Synthetic data only.",
    "phase": "Phase 2",
    "weight_loss_pct": 13.1,
    "gi_ae_pct": 22.7
  },
  {
    "abstract_id": "ADA-2026-PS-275",
    "title": "Danuglipron extended-release in T2D-obesity — Phase 2b interim (mock)",
    "authors": "Mock O",
    "abstract_text": "Danuglipron (PF-06882961) extended-release showed -8.7% placebo-adjusted body weight at 32 weeks in a synthetic Phase 2b cohort. GI AE 33.1%. Mock data; not a real clinical readout.",
    "phase": "Phase 2b",
    "weight_loss_pct": 8.7,
    "gi_ae_pct": 33.1
  }
]